Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

Annals of Internal Medicine(2020)10.7326/m19-2936Source: DataRank Database

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts is a research paper published in Annals of Internal Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 278 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access278 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 17.84)OA: greenTopics (60)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Brenda M. Sandmaier ORCID,Marco Mielcarek ORCID,Mohamed L. Sorror ORCID,Steven A. Pergam ORCID,Guang‐Shing Cheng ORCID

Live enrichment

PubMed:31958813 PMC:PMC7847247 OpenAlex:https://openalex.org/W3001829780

American Cancer Society

Grant: Research Scholar Grant No. RSG-13-084-01-CPHPS

Patient-Centered Outcome Research Institute

Grant: Contract No. CE-1304-7451

National Institutes of Health

Grant: CA18029, CA15704, CA78902, HL36444, HL088201, HL088021, HL096831, DK063038, HL122173, HL108307

NHLBI NIH HHS

Grant: K23 HL096831

NCI NIH HHS

Grant: P01 CA078902

NHLBI NIH HHS

Grant: R01 HL088201

NIDDK NIH HHS

Grant: K23 DK063038

NHLBI NIH HHS

Grant: K99 HL088021

NHLBI NIH HHS

Grant: P01 HL036444

NCI NIH HHS

Grant: P30 CA015704

NHLBI NIH HHS

Grant: R00 HL088021

NCI NIH HHS

Grant: P01 CA018029

NHLBI NIH HHS

Grant: P01 HL122173

NHLBI NIH HHS

Grant: R01 HL108307

National Institutes of Health

Grant: 2R01HL063038-09A2

Molecular Physiology of Myocardial Troponin I Variants

National Institutes of Health

Grant: 5R00HL088021-05

Impact of Comorbidities on Outcomes of Allogeneic Transplantation

National Institutes of Health

Grant: 5P01CA018029-36

Targeting Alloreactivity for Leukemia Eradication

National Institutes of Health

Grant: 3P30CA015704-42S2

Cancer Center Support Grant

National Institutes of Health

Grant: 5K23HL096831-03

Natural Killer Cell Receptor Diversity and CMV in Hematopoietic Cell Transplantat

National Institutes of Health

Grant: 2P01CA078902-16

Core C: Administrative Services

National Institutes of Health

Grant: 5R01HL088201-04

Genetic Analysis of Airflow Obstruction After Stem Cell Transplantation

FWCI

17.84

Citation Percentile

1.0%

Citation Trend

2012

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.acpjournals.org/journal/aim/text-and-data-mining

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7847247

publisherhttps://www.acpjournals.org/doi/pdf/10.7326/M19-2936

publisherhttps://www.acpjournals.org/doi/full-xml/10.7326/M19-2936

publisherhttps://annals.org/aim/fullarticle/2759352/survival-nonrelapse-mortality-relapse-related-mortality-after-allogeneic-hematopoietic-cell

Fields of Study

Hematopoietic Stem Cell TransplantationCytomegalovirus and herpesvirus researchViral-associated cancers and disorders01 natural sciences03 medical and health sciences0302 clinical medicine0101 mathematics

MeSH Terms

AdolescentAdultAgedChildChild, PreschoolFemaleHumansImmunosuppressive AgentsInfantMaleMiddle AgedNeoplasmsPrednisoneRecurrenceRisk FactorsTransplantation, HomologousProportional Hazards ModelsSurvival AnalysisTreatment OutcomeHematopoietic Stem Cell TransplantationYoung Adult

Keywords

MedicineHazard ratioInternal medicineTransplantationHematopoietic stem cell transplantationRegimenCancerSerostatusOncologySurgeryImmunologyConfidence intervalViral loadAdultMaleAdolescentInfantMiddle AgedSurvival AnalysisTreatment OutcomeRecurrenceRisk FactorsChild, PreschoolNeoplasmsHumansPrednisoneTransplantation, HomologousFemaleChildImmunosuppressive AgentsAgedProportional Hazards Models

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being